Literature DB >> 30806318

Mycobacterial tuberculosis Enzyme Targets and their Inhibitors.

Anil Kumar Saxena1, Anamika Singh1.   

Abstract

Tuberculosis (TB) still continues to be a major killer disease worldwide. Unlike other bacteria Mycobacterium tuberculosis (Mtb) has the ability to become dormant within the host and to develop resistance. Hence efforts are being made to overcome these problems by searching for new antitubercular agents which may be useful in the treatment of multidrug-(MDR) and extensively drugresistant (XDR) M. tuberculosis and shortening the treatment time. The recent introduction of bedaquiline to treat MDR-TB and XDR-TB may improve the status of TB treatment. The target enzymes in anti-TB drug discovery programs play a key role, hence efforts have been made to review the work on molecules including antiTB drugs acting on different enzyme targets including ATP synthase, the target for bedaquiline. Literature searches have been carried out to find the different chemical molecules including drugs and their molecular targets responsible for their antitubercular activities in recent years. This review provides an overview of the chemical structures with their antitubercular activities and enzyme targets like InhA, ATP synthase, Lip Y, transmembrane transport protein large (MmpL3), and decaprenylphospho-β-D-ribofuranose 2-oxidase, (DprE1). The major focus has been on the new target ATP synthase. Such an attempt may be useful in designing new chemical entities (NCEs) for specific and multi-drug targeting against Mtb. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  ATP; Enzyme targets; Inhibitors; Minimum inhibitory concentration (MIC); Mycobacterium tuberculosis; Tuberculosiszzm321990(TB).

Mesh:

Substances:

Year:  2019        PMID: 30806318     DOI: 10.2174/1568026619666190219105722

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  10 in total

1.  Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.

Authors:  Wenhu Zhan; Hao-Chi Hsu; Trevor Morgan; Tierra Ouellette; Kristin Burns-Huang; Ryoma Hara; Adrian G Wright; Toshihiro Imaeda; Rei Okamoto; Kenjiro Sato; Mayako Michino; Manoj Ramjee; Kazuyoshi Aso; Peter T Meinke; Michael Foley; Carl F Nathan; Huilin Li; Gang Lin
Journal:  J Med Chem       Date:  2019-10-15       Impact factor: 7.446

2.  Synthesis and Biological Evaluation of Novel Benzhydrylpiperazine-Coupled Nitrobenzenesulfonamide Hybrids.

Authors:  Vallabhaneni S Murthy; Yasinalli Tamboli; Vagolu Siva Krishna; Dharmarajan Sriram; Fang Xiong Zhang; Gerald W Zamponi; Vijayaparthasarathi Vijayakumar
Journal:  ACS Omega       Date:  2021-03-31

Review 3.  Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients.

Authors:  Giulia Degiacomi; José Camilla Sammartino; Laurent Roberto Chiarelli; Olga Riabova; Vadim Makarov; Maria Rosalia Pasca
Journal:  Int J Mol Sci       Date:  2019-11-22       Impact factor: 5.923

4.  Quantitative structure-activity relationship (QSAR) and molecular docking of xanthone derivatives as anti-tuberculosis agents.

Authors:  Emmy Yuanita; Ni Komang Tri Dharmayani; Maria Ulfa; Jufrizal Syahri
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-11-16

Review 5.  Addressing Latent Tuberculosis: New Advances in Mimicking the Disease, Discovering Key Targets, and Designing Hit Compounds.

Authors:  André Campaniço; Shrika G Harjivan; Digby F Warner; Rui Moreira; Francisca Lopes
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

6.  Identification of New Mycobacterium tuberculosis Proteasome Inhibitors Using a Knowledge-Based Computational Screening Approach.

Authors:  Tahani M Almeleebia; Mesfer Al Shahrani; Mohammad Y Alshahrani; Irfan Ahmad; Abdullah M Alkahtani; Md Jahoor Alam; Mohd Adnan Kausar; Amir Saeed; Mohd Saeed; Sana Iram
Journal:  Molecules       Date:  2021-04-16       Impact factor: 4.411

7.  Synthesis and Assessment of the In Vitro and Ex Vivo Activity of Salicylate Synthase (Mbti) Inhibitors as New Candidates for the Treatment of Mycobacterial Infections.

Authors:  Matteo Mori; Giovanni Stelitano; Anna Griego; Laurent R Chiarelli; Giulia Cazzaniga; Arianna Gelain; Elena Pini; Marina Camera; Paola Canzano; Andrea Fumagalli; Edoardo Scarpa; Chiara Cordiglieri; Loris Rizzello; Stefania Villa; Fiorella Meneghetti
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-11

8.  Identification of hydantoin based Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1) inhibitors as antimycobacterial agents using computational tools.

Authors:  Suraj N Mali; Anima Pandey; Richie R Bhandare; Afzal B Shaik
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

Review 9.  Mycobacterium tuberculosis β-Carbonic Anhydrases: Novel Targets for Developing Antituberculosis Drugs.

Authors:  Ashok Aspatwar; Visvaldas Kairys; Sangeetha Rala; Mataleena Parikka; Murat Bozdag; Fabrizio Carta; Claudiu T Supuran; Seppo Parkkila
Journal:  Int J Mol Sci       Date:  2019-10-17       Impact factor: 5.923

Review 10.  Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer.

Authors:  Yu Cao; Huajian Zhu; Ruoyu He; Limin Kong; Jiaan Shao; Rangxiao Zhuang; Jianjun Xi; Jiankang Zhang
Journal:  Drug Des Devel Ther       Date:  2020-10-19       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.